SOSAFE
24.5.2024 10:41:26 CEST | Business Wire | Press release
SoSafe, Europe’s largest security awareness and human risk management vendor, has announced the launch of their pioneering Human Risk Operating System, The Human Risk OS™, a set of capabilities designed to help customers identify, quantify, monitor, and intervene on human security risk. SoSafe has also presented new capabilities to its Sofie Human Security Copilot, an AI-powered multi-channel agent built entirely on advanced Large Language Models, as well as incremental updates to its flagship product offering such as next-level personalized learning, behavioral phishing simulation, novel security operations and 3rd party data integrations. With that, SoSafe is leading the category evolution from security awareness to human risk management in response to escalating cyber threats and the need for security strategies to address human risk more holistically.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524947770/en/
SoSafe launches The Human Risk OS™, bringing together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. Copyright: SoSafe GmbH
Dr Niklas Hellemann, Psychologist and CEO at SoSafe: “To achieve real risk reduction and meet the demands of security leaders, basic awareness measures alone don’t cut it. While traditional and generic awareness programs focus on awareness and knowledge transfer–educating individuals about potential threats and instructing them on response strategies–this approach often falls short in today’s dynamic environment. The evolving landscape requires an evolution to holistic human risk management, which prioritizes the outcomes and the drivers of behavior and helps to sustainably mitigate human risks.”
The Human Risk OS™ brings together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. It focuses on proactively managing security risks through real-time risk detection and continuous analyses, provides enhanced behavioural insights and recommends targeted interventions to customize and optimize defensive responses.
Its three core elements are:
- Human Behavior Sensors measure an organization’s digital activities, behaviors, and security culture, creating individual and group-level profiles of security behavior.
- The Human Security Index processes this tracked data and additional contextual information such as level of seniority, tenure, digital access, and functional criticality to create a single index that summarizes security performance for groups and organizations. This score allows organizations to quickly identify concern areas, track progress, and evolution over time, and the impact of different possible interventions.
- The Intervention Hub suggests intervention strategies to mitigate human-related security risks and drive behavioral change and healthy security.
Gonçalo Gaiolas, CPO at SoSafe: “We believe in the power of people in the fight against cybercrime. With The Human Risk OS™, organizations invest in more than just a security solution—they invest in a proactive approach to mitigating human-centric risk and securing their organization's future by putting people at the very center of their efforts. We empower organizations to drive behavioral change and build security cultures by identifying, quantifying, actively managing, and reducing their human risk and by focusing on efficiency to relieve the pressure on overstretched security teams.”
SoSafe also introduced additional capabilities to its “Sofie Human Security Copilot”, an AI-powered multi-channel agent built to meaningfully reduce human risk. Sofie supports security professionals and users with rapid threat awareness, situational awareness, and zero-level security and compliance support. Security leaders can now incorporate organisational policies and specifics into their responses. Built on advanced large language models and featuring an engaging interface, Sofie provides answers to support questions at any time, sends urgent security alerts, and educates users on security best practices, all customized to specific organizational needs and policies.
Unlike other conversational AI-solutions, Sofie focuses on making each interaction with the end user a learning moment in their daily work environment, not just delivering informative content, but also aiming to change behavior.
Gonçalo Gaiolas: “Cybercriminals are already harnessing the power of AI to enhance their social engineering attacks. It's time to use the full potential of AI on the defensive side as well. Our AI-powered multi-channel agent ‘Sofie’ demonstrates the power of AI for cyber defenses: It’s a multifunctional tool that makes security information accessible to everyone anytime, provides learning opportunities in every interaction, and supports security administrators with content and communication, automating responses to free up their team’s capacity. ‘Sofie’ makes cybersecurity part of our everyday work, manifesting security cultures as the most essential part of holistic human risk management.”
Ilona Simpson, longstanding CIO and Executive Advisor at SoSafe: “SoSafe’s Human Risk OS™ and Sofie help security leaders to efficiently drive a human risk management strategy that sustainably mitigates risk. Based on behavioral data and fueled with new technology, SoSafe simplifies where others complicate, making it easy for security professionals to strengthen the human layer as the most versatile part of our defense strategy. SoSafe's focus on automation and efficiency not only saves security teams significant time but also amplifies their results, enhancing overall security posture.”
SoSafe presented its product innovations “The Human Risk OS™” and “Sofie Human Security Copilot” with its new capabilities during a launch event on May 23rd in Cologne, Germany and via livestream in front of more than 300 industry guests.
About SoSafe
SoSafe, founded by a team of behavioral scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioral science, SoSafe enhances secure behavior across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defense by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240524947770/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
